RPL 554

Drug Profile

RPL 554

Alternative Names: RPL554

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Allergic rhinitis; Asthma; Asthma

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
  • Discontinued Allergic rhinitis

Most Recent Events

  • 21 May 2018 Updated efficacy data from a phase IIa clinical trial inChronic obstructive pulmonary disease presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 21 May 2018 Verona Pharma plans clinical trials for pressurised metered dose inhaler and dry powder inhaler formulations of RPL 554 for Chronic obstructive pulmonary disease (In volunteers) in the first quarter of 2019
  • 18 May 2018 Adverse events and pharmacokinetics data from a phase I study in Healthy volunteers presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top